WuXi Biologics (Cayman) Inc.
WXIBF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.40 | 0.28 | 0.21 | -0.52 |
| FCF Yield | -0.10% | 2.87% | -1.31% | 0.19% |
| EV / EBITDA | 27.04 | 15.50 | 15.60 | 53.10 |
| Quality | ||||
| ROIC | 4.11% | 4.74% | 3.20% | 2.48% |
| Gross Margin | 42.73% | 42.58% | 39.07% | 38.25% |
| Cash Conversion Ratio | 0.77 | 1.17 | 0.87 | 1.37 |
| Growth | ||||
| Revenue 3-Year CAGR | 44.20% | 54.96% | 65.65% | 70.49% |
| Free Cash Flow Growth | -105.05% | 427.79% | -358.59% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -0.97 | -0.84 | -1.85 | -2.40 |
| Interest Coverage | 0.00 | 20.02 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.44 | 3.81 | 2.66 | 2.99 |
| Cash Conversion Cycle | 74.38 | 63.58 | 83.60 | 81.07 |